



Wednesday, December 6, 2023

## **Presentations** at the San Antonio Breast Cancer Symposium

All times listed are Central Standard Time. Times and locations subject to change by SABCS.

<b>Presentation</b>	<b>Speaker</b>	<b>Time/Location</b>
<b>Liquid biopsy determination of HER2 status in breast cancer: results from a novel epigenomic platform</b>  Concurrent Poster Spotlight Session Block 2: PS06 Prognostic and predictive uses of cell free DNA	Heather Parsons, MD, MPH	7 – 8 a.m.  Stars at Night Ballroom 1-2
<b>Debate: Anthracyclines...To give or not to give?</b>	Harold Burstein, MD, PhD Moderator	1 – 2 p.m.  Stars at Night Ballroom 1-2
<b>Biomarkers predicting immune related adverse events</b>  State-of-the-Art Session 1: Immunotherapy: Purpose, Resistance, and Toxicity	Toni Choueiri, MD	1 – 2 p.m.  Stars at Night Ballroom 3-4
<b>Molecular Tumor Board Panelist Discussion</b>	Nancy Lin, MD Panelist	2 – 3 p.m.  Hemisfair Ballroom 1-2
<b>Novel systemic therapy strategies for HER2+ brain metastases</b>  ED07: HER2+ Breast Cancer— Updates from the Clinic and the Lab	Sarah Sammons, MD	3:10 – 5 p.m.  Stars at Night Ballroom 1-2
<b>Next generation therapeutics in hormone positive breast cancer: Balancing efficacy and tolerability</b>  ED08: Toxicity Management— Next-Gen Therapies Means Next-Gen Toxicities	Erica Mayer, MD, MPH	3:10 – 5 p.m.  Stars at Night Ballroom 3-4
<b>Antibody Drug Conjugates: Where are We Headed?</b>  Concurrent Poster Spotlight Session Block 3	Sara Tolaney, MD, MPH Moderator	5:30 – 6:30 p.m.  Hemisfair Ballroom 1-2





Wednesday, December 6, 2023

---

**Discussant**

Ana Garrido-Castro, MD

5:30 – 6:30 p.m.

Hemisfair Ballroom 1-2

Concurrent Poster Spotlight Session Block 3:  
Antibody Drug Conjugates: Where are  
We Headed?

---

**Impact of HER2 expression dynamics on  
the real-world activity of trastuzumab  
deruxtecan for metastatic breast  
cancer (RELIEVE)**

Paolo Tarantino, MD

5:30 – 6:30 p.m.

Hemisfair Ballroom 1-2

Concurrent Poster Spotlight Session Block 3:  
Antibody Drug Conjugates: Where are  
We Headed?

---

**Event-free Survival by Residual Cancer  
Burden (RCB) and Intratumor HER2  
Heterogeneity after Neoadjuvant T-DM1 and  
Pertuzumab for Early-stage HER2-positive  
Breast Cancer**

Otto Metzger, MD

5:30 – 6:30 p.m.

Stars at Night  
Ballroom 1-2

Concurrent Poster Spotlight Session Block 3:  
Exploiting tumor biology in HER2-positive  
breast cancer to escalate or de-escalate  
neoadjuvant therapy

---